ClinicalTrials.gg
TerminatedNCT00758342Updated Dec 5, 2023Results posted

Azopt (Brinzolamide 1.0%) Plus Travatan (Travoprost 0.004%) in Treating Patients With Chronic Angle-Closure Glaucoma (CACG)

A Phase 4 interventional study of Travoprost 0.004% + Brinzolamide 1.0% and Travoprost 0.004% + Tears Natural in Intraocular Pressure, sponsored by Alcon Research. Terminated. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-12-05.

Sponsored by Alcon Research (part of Alcon) · Phase 4, Interventional, and Treatment

Why this study was terminated
difficulty of enrolling patients

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
37
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

To evaluate the IOP (Intraocular Pressure) lowering efficacy and safety of Brinzolamide 1.0% (Azopt), dosed twice daily as adjunctive therapy in patients treated with Travoprost 0.004% (Travatan) once daily. The study is double masked. The patients will receive either treatment for 12 weeks.

02

Conditions studied

  • Intraocular Pressure

Keywords

  • IOP lowering efficacy and safety of Azopt plus Travatan
03

In context

Lead sponsor

Alcon Research is the lead sponsor of 624 studies on the registry; 9 are open to participants now.

Of its 112 completed or terminated interventional studies of FDA-regulated products, 102 (91%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥ 18 years;
  • CACG (Chronic Angle Closure Glaucoma) ≥ 1eye
  • have been treated with PGA (prostaglandin analogues) once daily ≥ 2 weeks prior to the screening visit and IOP=19-32 mmHg (millimeters mercury) in at least one eye and ≤ 32 mmHg in both eyes
  • clinical stability of VA (Visual Acuity) and optic nerve throughout the study

Exclusion criteria

Exclusion Criteria:

  • Abnormality restricts exam of the fundus or anderior chamber
  • conjunctivitis, keratitis or uveitis
  • unable to be discontinued from using all ocular hypotensive medication(s) except Travatan (Travoprost 0.004%) and/or Azopt (Brinzolamide 1.0%) for 12days-4weeks
  • ocular surgery prior to the study
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
37 participants (actual)

Study arms

  • Experimental
    Travoprost 0.004% + Brinzolamide 1.0%

    Travoprost 0.004% (once daily) + Brinzolamide 1.0% (twice daily)

    Drug: Travoprost 0.004% + Brinzolamide 1.0%

  • Active comparator
    Travoprost 0.004% + Tears Natural

    Travoprost 0.004% (once daily) + Tears Naturale (twice daily)

    Drug: Travoprost 0.004% + Tears Natural

Interventions

  • DrugTravoprost 0.004% + Brinzolamide 1.0%

    Drug page: Travoprost

    Travoprost 0.004% (once daily) + Brinzolamide 1.0% (twice daily)

  • DrugTravoprost 0.004% + Tears Natural

    Drug page: Travoprost

    Travoprost 0.004% (once daily) + Tears Naturale (twice daily)

06

What researchers measure

Primary outcomes

  1. Mean IOP (Intraocular Pressure)

    Time frame: Screening: Week 12; (At 9 am and 4 pm time points)

07

Results

Posted Feb 5, 2010

Participant flow

Participant flow — Overall Study
MilestoneTravoprost 0.004% + Brinzolamide 1.0%Travoprost 0.004% + Tears Natural
Started1918
Completed1517
Not completed41

Outcome measures

PrimaryMean IOP (Intraocular Pressure)
Time frame:
Screening: Week 12; (At 9 am and 4 pm time points)
Reported as:
Mean · mm Hg (millimeters mercury)
Mean IOP (Intraocular Pressure)
mm Hg (millimeters mercury)Travoprost 0.004% + Brinzolamide 1.0%Travoprost 0.004% + Tears Natural
9 AM measurement17.58 ± 4.2920.59 ± 3.70
4 PM measurement17.11 ± 4.5018.50 ± 3.05

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Travoprost 0.004% + Brinzolamide 1.0%—0/19 (0%)0/19 (0%)
Travoprost 0.004% + Tears Natural—0/18 (0%)0/18 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Travoprost 0.004% + Brinzolamide 1.0%Travoprost 0.004% + Tears NaturalTotal
<=18 years000
Between 18 and 65 years111526
>=65 years8311
Sex: Female, Male
Sex: Female, Male(Participants)Travoprost 0.004% + Brinzolamide 1.0%Travoprost 0.004% + Tears NaturalTotal
Female141125
Male5712
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2006, a primary completion of Mar 2008 and a completion of Mar 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2010, 1 year 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2008
First posted
Sep 25, 2008
Start
May 2006
Primary completionActual
Mar 2008
CompletionActual
Mar 2008
Results first posted
Feb 5, 2010
Last update
Dec 5, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 5, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00758342
Lead sponsor
Alcon Research
Responsible party
Sponsor
First posted
Sep 25, 2008
Start date
May 2006
Primary completion
Mar 2008
Completion
Mar 2008
Results posted
Feb 5, 2010
Last update
Dec 5, 2023

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Travoprost

Start the discussion